Is Coeptis Therapeutics Holdings, Inc. (COEP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.8% / 30% | 0.7% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.8% / 33% | 0.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 15.7% / 33% | 6.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 1.8% / 33% | 0.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 15.7% / 33% | 6.0% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 86.7% | |
| Operating Margin | -230.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -136.9% | |
| Return on Assets (ROA) | -65.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $1M |
| Debt-to-Equity | 1.9 |
| Current Ratio | 4.2 |
| Total Assets | $9M |
Price & Trading
| Last Close | $10.92 |
| 50-Day MA | $12.29 |
| 200-Day MA | $13.10 |
| Avg Volume | 54K |
| Beta | -0.5 |
|
52-Week Range
$6.26
| |
About Coeptis Therapeutics Holdings, Inc. (COEP)
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR cells co-administered with one or more antibody adaptors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Further, it provides NexGenAI Affiliates Network platform, which includes AI-powered marketing software and robotic process automation capabilities. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Coeptis Therapeutics Holdings, Inc. (COEP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Coeptis Therapeutics Holdings, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Coeptis Therapeutics Holdings, Inc.'s debt ratio?
Coeptis Therapeutics Holdings, Inc.'s debt ratio is 1.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 15.7%.
What are Coeptis Therapeutics Holdings, Inc.'s key financial metrics?
Coeptis Therapeutics Holdings, Inc. has a market capitalization of $66M. Return on equity stands at -136.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.